PRESENTATION
RosuvaTM
5 Tablet: Each film coated tablet contains Rosuvastatin Calcium INN equivalent to 5 mg Rosuvastatin.
RosuvaTM 10 Tablet: Each film coated tablet contains Rosuvastatin Calcium INN equivalent to 10 mg Rosuvastatin.
RosuvaTM
20 Tablet: Each film coated tablet contains Rosuvastatin Calcium INN equivalent to 20 mg Rosuvastatin.
PHARMACOLOGY
RosuvaTM
(Rosuvastatin) is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting
enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of
cholesterol. Rosuvastatin produces its lipid-modifying effects in two ways. First, it increases the number
of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL. Second,
Rosuvastatin inhibits hepatic synthesis of VLDL,which reducesthe total number of VLDL and LDL particles.
PHARMACOKINETICS
Absorption
Peak plasma concentrations of Rosuvastatin were reached 3 to 5 hours following oral dosing. Both peak
concentration (Cmax) and area under the plasma concentration-time curve (AUC) increased in
approximate proportion to Rosuvastatin dose.
Distribution
Mean volume of distribution at steady-state of Rosuvastatin is approximately 134 liters. Rosuvastatin is
88% bound to plasma proteins, mostly albumin.
Metabolism
Rosuvastatin is not extensively metabolized. The major metabolite of Rosuvastatin is N-desmethyl
rosuvastatin which has approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity
of Rosuvastatin. Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is
accounted for by Rosuvastatin.
Elimination
Following oral administration, Rosuvastatin and its metabolites are primarily excreted in the feces
(90%).The elimination half-life (t
1/2) of Rosuvastatin is approximately 19 hours.
INDICATION AND USE
Heterozygous Hypercholesterolemia (Familial and Nonfamilial)
Homozygous Hypercholesterolemia (Familial)
Mixed Dyslipidemia (Fredrickson Type IIa and IIb)
DOSAGE AND ADMINISTRATION
Heterozygous Hypercholesterolemia (Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Type
IIa and IIb)
The usual recommended starting dose of Rosuvastatin is 10 mg once daily. Initiation of therapy with 5
mg once daily may be considered for patients requiring less aggressive LDL-C reductions or who have
predisposing factors for myopathy. For patients with marked hypercholesterolemia (LDL-C > 190
mg/dL) and aggressive lipid targets, a 20 mg starting dose may be considered. The 40 mg dose of
Rosuvastatin should be reserved for those patients who have not achieved goal LDL-C at 20 mg. After
initiation and/or upon titration of Rosuvastatin, lipid levels should be analyzed within 2 to 4 weeks and
dosage adjusted accordingly.
Homozygous Hypercholesterolemia (Familial)
The recommended starting dose of Rosuvastatin is 20 mg once daily in patients with homozygous FH.
The maximum recommended daily dose is 40 mg. Rosuvastatin should be used in these patients as an
adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.
Patients with renal insufficiency
No modification of dosage is necessary for patients with mild to moderate renal insufficiency. For
patients with severe renal impairment (CLcr <30 mL/min/1.73 m2) not on hemodialysis, dosing of
Rosuvastatin should be started at 5 mg once daily and not to exceed 10 mg once daily.
Dosage in Asian Patients
Initiation of Rosuvastatin therapy with 5 mg once daily should be considered for Asian patients.
Use with Cyclosporine, Lopinavir/Ritonavir or Atazanavir/Ritonavir
In patients taking Cyclosporine, the dose of Rosuvastatin should be limited to 5 mg once daily. In
patients taking Lopinavir and Ritonavir or Atazanavir and Ritonavir the dose of Rosuvastatin should be
limited to 10 mg once daily.
CONTRAINDICATION
Rosuvastatin is contraindicated in patients with a known hypersensitivity to any component of this
product. Rosuvastatin is contraindicated in patients with active liver disease or with unexplained
persistent elevations of serum transaminases.
SIDE EFFECT
Rosuvastatin is generally well tolerated. The most frequent adverse events thought to be related to
Rosuvastatin were myalgia, constipation, asthenia, abdominal pain, and nausea.
DRUG INTERACTION
Erythromycin: Co-administration of Erythromycin with Rosuvastatin decreased AUC and Cmax of
Rosuvastatin by 20% and 31%, respectively. Itraconazole: Itraconazole resulted in a 39% and 28%
increase in AUC of Rosuvastatin after 10 mg and 80 mg dosing, respectively. Fluconazole: Coadministration
of Fluconazole with Rosuvastatin resulted in a 14% increase in AUC of Rosuvastatin.
Warfarin: Co-administration of Warfarin (25 mg) with Rosuvastatin (40 mg) did not change Warfarin
plasma concentrations but increased the International Normalized Ratio (INR). Gemfibrozil: Coadministration
of Gemfibrozil (600 mg twice daily for 7 days) with Rosuvastatin (80 mg) resulted in a
90% and 120% increase for AUC and Cmax of Rosuvastatin, respectively. Antacid: Co-administration of
an antacid (aluminum and magnesium hydroxide combination) with Rosuvastatin (40 mg) resulted in a
decrease in plasma concentrations of Rosuvastatin by 54%. Oral contraceptives: Co-administration of
oral contraceptives (Ethinyl Estradiol and Norgestrel) with Rosuvastatin resulted in an increase in
plasma concentrations of Ethinyl Estradiol and Norgestrel by 26% and 34%,respectively.
USE IN PREGNANCY AND LACTATION
Rosuvastatin should be administered to women of childbearing age only when such patients are
highly unlikely to conceive and have been informed of the potential hazards. If the patient becomes
pregnant while taking this drug, therapy should be discontinued immediately. It is not known whether
Rosuvastatin is excreted in human milk.
Rosuva 20mg 1pcs
৳ 30
Description
Reviews (0)
Be the first to review “Rosuva 20mg 1pcs” Cancel reply
Reviews
There are no reviews yet.